1. Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria.
- Author
-
Li C, Stražar M, Mohamed AMT, Pacheco JA, Walker RL, Lebar T, Zhao S, Lockart J, Dame A, Thurimella K, Jeanfavre S, Brown EM, Ang QY, Berdy B, Sergio D, Invernizzi R, Tinoco A, Pishchany G, Vasan RS, Balskus E, Huttenhower C, Vlamakis H, Clish C, Shaw SY, Plichta DR, and Xavier RJ
- Subjects
- Humans, Feces chemistry, Longitudinal Studies, Metabolome, Metabolomics, RNA, Ribosomal, 16S metabolism, Bacteria metabolism, Cardiovascular Diseases metabolism, Cholesterol analysis, Cholesterol blood, Cholesterol metabolism, Gastrointestinal Microbiome
- Abstract
Accumulating evidence suggests that cardiovascular disease (CVD) is associated with an altered gut microbiome. Our understanding of the underlying mechanisms has been hindered by lack of matched multi-omic data with diagnostic biomarkers. To comprehensively profile gut microbiome contributions to CVD, we generated stool metagenomics and metabolomics from 1,429 Framingham Heart Study participants. We identified blood lipids and cardiovascular health measurements associated with microbiome and metabolome composition. Integrated analysis revealed microbial pathways implicated in CVD, including flavonoid, γ-butyrobetaine, and cholesterol metabolism. Species from the Oscillibacter genus were associated with decreased fecal and plasma cholesterol levels. Using functional prediction and in vitro characterization of multiple representative human gut Oscillibacter isolates, we uncovered conserved cholesterol-metabolizing capabilities, including glycosylation and dehydrogenation. These findings suggest that cholesterol metabolism is a broad property of phylogenetically diverse Oscillibacter spp., with potential benefits for lipid homeostasis and cardiovascular health., Competing Interests: Declaration of interests R.J.X. is a member of the Scientific Advisory Boards at Nestlé and Magnet Biomedicine, a founder of Jnana and Celsius Therapeutics, and a board member of MoonLake Immunotherapeutics. A provisional patent application describing potential treatments for CVD using the isolates and related compositions described in this study has been filed. The authors listed on that application are R.J.X., C.L., M.S., A.M.T.M, and D.R.P., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF